Onartuzumab

Onartuzumab
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	scatter factor receptor kinase
Clinical data
ATC code	none;
Identifiers
CAS Number	1133766-06-9 ;
ChemSpider	none;
UNII	MS1J9720WC;
Chemical and physical data
Formula	C4422H6820N1168O1363S31
Molar mass	99.1 kg/mol g·mol−1
	(what is this?) (verify)

Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.^[1]^[2]^[3]

Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials.^[4]^[5]^[6]^[7]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
^ Padda S, Neal JW, Wakelee HA (December 2012). "MET inhibitors in combination with other therapies in non-small cell lung cancer". Transl Lung Cancer Res. 1 (4): 238–53. doi:10.3978/j.issn.2218-6751.2012.10.08. PMC 4367550. PMID 25806189.
^ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F (May 2015). "Onartuzumab in lung cancer: the fall of Icarus?". Expert Rev Anticancer Ther. 15 (5): 487–9. doi:10.1586/14737140.2015.1031219. PMID 25818471.
^ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S (November 2013). "Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors". J Clin Pharmacol. 53 (11): 1103–11. doi:10.1002/jcph.148. PMID 23922054.
^ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H (November 2012). "Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer". Clin Lung Cancer. 13 (6): 500–4. doi:10.1016/j.cllc.2012.05.009. PMID 23063071.
^ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC (November 2013). "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer". J. Clin. Oncol. 31 (32): 4105–14. doi:10.1200/JCO.2012.47.4189. PMC 4878106. PMID 24101053.
^ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T (June 2015). "Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer". Invest New Drugs. 33 (3): 632–40. doi:10.1007/s10637-015-0227-5. PMID 25777467.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.

[2] Padda S, Neal JW, Wakelee HA (December 2012). "MET inhibitors in combination with other therapies in non-small cell lung cancer". Transl Lung Cancer Res. 1 (4): 238–53. doi:10.3978/j.issn.2218-6751.2012.10.08. PMC 4367550. PMID 25806189.

[3] Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F (May 2015). "Onartuzumab in lung cancer: the fall of Icarus?". Expert Rev Anticancer Ther. 15 (5): 487–9. doi:10.1586/14737140.2015.1031219. PMID 25818471.

[4] Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S (November 2013). "Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors". J Clin Pharmacol. 53 (11): 1103–11. doi:10.1002/jcph.148. PMID 23922054.

[5] Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H (November 2012). "Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer". Clin Lung Cancer. 13 (6): 500–4. doi:10.1016/j.cllc.2012.05.009. PMID 23063071.

[6] Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC (November 2013). "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer". J. Clin. Oncol. 31 (32): 4105–14. doi:10.1200/JCO.2012.47.4189. PMC 4878106. PMID 24101053.

[7] Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T (June 2015). "Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer". Invest New Drugs. 33 (3): 632–40. doi:10.1007/s10637-015-0227-5. PMID 25777467.

[1]

[2]

[3]

[4]

[5]

[6]

[7]